Recursion’s Post

🚀 Presenting ADC Digest for March 2024!🔬💊 This week, the realm of Antibody Drug Conjugates (ADCs) is buzzing with phenomenal breakthroughs! Here's a glimpse: 🌍 Samsung collaborates with BrickBio to pioneer cutting-edge molecules and therapies using protein engineering for ADCs 🌍 Antengene embarks on Phase II Dose Expansion Study of Claudin 18.2 ADC ATG-022 in China and Australia, marking a significant stride in cancer treatment 🌍 Korean patients edge closer to affordable access to revolutionary cancer therapy, Enhertu. Stay tuned as we bring you more updates from the dynamic world of ADCs! #ADC #Antibodydrugconjugate #ADCnews #CIScientists #CompetitiveIntelligence #MedicalAdvancements #HealthcareRevolution Stay tuned for more updates in the world of ADCs!

In a study funded by our division, Meisam Bagheri, Ph.D., Todd Miller, PhD, Diwakar Pattabiraman, et al. found that eribulin (an FDA-approved chemotherapeutic drug) induces chromatin remodeling to reverse epithelial to mesenchymal transition and sensitizes cancer cells to other chemotherapies in preclinical models of triple-negative #BreastCancer. https://lnkd.in/erd5cpTu

US Antibody Drug Conjugates Market: Revolutionizing Cancer Treatment with Targeted Therapies Get Free PDF: https://lnkd.in/dHV3kCAJ The US Antibody Drug Conjugates (ADCs) market is witnessing a remarkable surge, valued at USD 1.3 Billion in 2023 and projected to reach USD 3.50 Billion by 2030, with a robust CAGR of 15.2%. ADCs represent a groundbreaking approach in cancer treatment, merging potent cell-killing small molecule drugs with monoclonal antibodies to precisely target tumor cells while sparing healthy tissue. #ADCs #CancerTreatment #Oncology #InnovativeTherapies #PrecisionMedicine #Healthcare #MedicalInnovation

📢 New Publication Alert: Overcoming Drug Resistance with KRAS Inhibitors and Combination Therapy 📢 Excited to share our latest review article, KRAS Inhibitors in Drug Resistance and Potential for Combination Therapy, published in Tumori (Sage Journal Impact Factor 2.4) on November 6, 2024 The fight against cancer takes another step forward! 🧬 🦀 Kirsten Rat Sarcoma (KRAS) has proven to be a pivotal target in cancer therapy, driving cell differentiation, proliferation, and survival. Recently, the US FDA granted emergency approval for KRASG12C inhibitors (sotorasib and adagrasib) to treat metastatic lung cancer. However, early clinical studies have encountered rapid resistance to these treatments. In our recent review article published in Tumori, we dive into the challenges of resistance to covalent KRASG12C inhibitors and explore promising strategies to overcome these hurdles through combination therapies. With KRASG12D and KRASG12V mutations being more prevalent, the need for innovative therapeutic strategies for these variants is critical. Let’s continue advancing research and developing effective therapies to ensure better outcomes for all patients facing KRAS-driven cancers. 🧪 🔬💪  #https://lnkd.in/d2T7RrUJ #CancerResearch #KRASInhibitors #Oncology #DrugResistance #CombinationTherapy #CancerTreatment #KRASG12C #KRAS #Tumori #SageJournals #DSTSERB #Scopus #GoogleSchloar

Interferon alpha-2 enters the precision medicine era: Nammi Therapeutics, Inc. just dosed their first patient with QXL138AM, and the approach is rather clever. The science here is fascinating - instead of accepting the systemic toxicity that usually limits interferon therapy, they've created a masked immunocytokine that only activates at the tumor site. The antibody portion targets CD138+ cancer cells, the interferon stays masked until it reaches the tumor, and local proteases unmask it right where it needs to work. What's particularly interesting is how they're approaching development: starting with CD138+ cancers ✓ potential for both solid tumors and multiple myeloma ✓ already secured Orphan Drug Designation in pancreatic cancer ✓ and planning to let early clinical data guide their expansion strategy. Could this finally be the way to harness interferon's anti-cancer potential without the systemic side effects? #CancerTherapy #PrecisionMedicine #Immunocytokines #ClinicalTrials

💕 "BREAKING---   😆 1st article in our SPECIAL ISSUE: "#Mechanisms of Targeted Therapy #Resistance and #ReversalStrategies" is out NOW! Don't miss the latest insights! #TargetedTherapy #ResistanceReversal #CancerResearch"   Academic Editor: Pier Paolo Piccaluga, University of Bologna, Italy    📚 In this review, authors describe the characteristics of TIS in breast cancer and detail the changes in phenotype that accompany its induction. We also discuss strategies for targeting senescent cancer cells in order to prevent or delay tumour recurrence.   🎬 Therapy-induced senescence in #BreastCancer: an overview   📝 Authors: Suraj Narayanan Chembukavu , Andrew J Lindsay *    🏃♂️ Welcome to read, forward, and share the article! https://lnkd.in/gxvth5Y2   #DrugResistance, therapy-induced senescence, #MembraneTrafficking, #IronMetabolism, #Senotherapeutics

Colorectal Cancer Screening Enhanced: FDA Approves ColoSense mt-sRNA Test for Early Detection The FDA has approved ColoSense, a multitarget stool RNA test, for colorectal cancer screening in adults aged 45 or older who are at average risk. The test detects colorectal neoplasia-associated RNA markers and occult hemoglobin in stool, and a positive result may indicate the presence of colorectal cancer, advanced adenomas, or precancerous lesions. The approval was based on the outcomes of the CRC-PREVENT trial, which showed that ColoSense accurately identifies colorectal abnormalities. The test offers a reliable and convenient option for screening, potentially leading to earlier detection and improved patient outcomes. ColoSense is expected to be launched in the United States later this year or in early 2025. For more details please click the link! https://lnkd.in/dvRdWuAC #marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical

A study supported by Zai Lab (NASDAQ: ZLAB, SEHK: 9688) has been published in the prestigious Cell journal. This NANT study reveals that the PARP inhibitor niraparib, as a neoadjuvant monotherapy, shows a high response rate and remodels the tumor microenvironment (TME). This provides new targets for immunotherapy and combination therapies for patients with homologous recombination deficiency (HRD) positive ovarian cancer. The research demonstrates that niraparib preferentially inhibits certain immune cells that support HRD-positive ovarian tumor growth. The study also highlights that Zai Lab's proprietary CCR8 antibody, ZL-1218, can significantly enhance the sensitivity of HRD tumors to niraparib by targeting and clearing infiltrating regulatory T cells (eTreg), thereby reducing tumor burden in preclinical models. #CancerResearch #Immunotherapy #Oncology #HRD #PARPInhibitor #CellJournal #Biotech #PharmaInnovations #QimingPortfolio #QimingHealthcare

In a study funded by the Cancer Systems Biology Consortium (CSBC), Brooke Brown , Matthew Lazzara, et al. found that the hypoxic (i.e. low oxygen) #PancreaticCancer microenvironment drives epithelial-mesenchymal transition (EMT) that promotes chemoresistance through a histone methylation-MAPK signaling positive-feedback loop. They further showed that combinations of MAPK inhibitors suppress hypoxia-driven EMT in preclinical models of pancreatic cancer, which may be a potential therapeutic strategy to overcome drug resistance. https://lnkd.in/eaeJDG_C

ANGLE PLC (AIM:AGL, OTCQX:ANPCY), the developer of liquid biopsy technologies, has partnered with AstraZeneca PLC (LSE:AZN) to enhance cancer drug development by 'leveraging' the former's DNA damage response assay. Specifically, the collaboration will focus on adapting ANGLE's existing Parsortix-based assay for identifying micronuclei in circulating tumour cells (CTCs), a crucial step in studying DNA damage responses. Ultimately, the assay aims to provide a repeatable, minimally invasive tool for better understanding and targeting tumour-specific DNA repair mechanisms, which could lead to more effective cancer treatments. More at #Proactive #ProactiveInvestors #angleplc biopsy http://ow.ly/qYFP105qBtS